Table 3 Most common CGH alterations in transformed DLBCL as compared to preceding FL as well as de novo DLBCL
From: Genomic imbalances during transformation from follicular lymphoma to diffuse large B-cell lymphoma
Data from alteration | This study, FL (n=18) | P-value | This study, transformed DLBCL (n=28) | P-value | Berglund et al17 de novo DLBCL (n=33) |
|---|---|---|---|---|---|
+Xq25–26 | 5/18 (28%) | NS (0.6) | 10/28 (36%) | NS (0.4) | 15/33 (45%) |
−1q34-qter | 0/18 (0%) | NS (0.2) | 3/28 (11%) | NS (0.2) | 8/33 (24%) |
+1q31–32 | 4/18 (23%) | NS (0.5) | 4/28 (14%) | NS (0.07) | 2/33 (6%) |
+3q24–25 | 0/18 (0%) | NS (0.4) | 1/28 (4%) | 0.04 | 7/33 (21%) |
−4q13–21 | 1/18 (6%) | NS (0.4) | 4/28 (14%) | 0.02 | 0/33 (0%) |
−6q16–21 | 0/18 (0%) | 0.02 | 7/28 (25%) | NS (0.9) | 8/33 (24%) |
+7pter-q22 | 0/18 (0%) | 0.02 | 7/28 (25%) | NS (0.3) | 5/33 (15%) |
−8p22-pter | 1/18 (6%) | NS (0.2) | 5/28 (18%) | NS (0.5) | 8/33 (24%) |
+8q21.3–22 | 0/18 (0%) | NS (0.06) | 5/28 (18%) | NS (0.5) | 4/33 (12%) |
−9p23-pter | 1/18 (6%) | NS (0.5) | 3/28 (11%) | NS (0.9) | 4/33 (12%) |
+11q22 | 1/18 (6%) | NS (0.2) | 5/28 (18%) | NS (0.8) | 5/33 (15%) |
+12q15 | 2/18 (11%) | NS (0.2) | 8/28 (29%) | NS (0.7) | 8/33 (24%) |
+13q22 | 1/18 (6%) | NS (0.8) | 2/28 (7%) | 0.01 | 11/33 (33%) |
−15q15-qter | 1/18 (6%) | NS (0.4) | 4/28 (14%) | NS (0.3) | 2/33 (6%) |
−17p | 4/18 (23%) | NS (0.7) | 5/28 (18%) | NS (0.7) | 7/33 (21%) |
+18q21 | 6/18 (33%) | NS (0.4) | 6/28 (21%) | NS (0.8) | 8/33 (24%) |
+21q | 1/18 (6%) | NS (0.4) | 4/28 (14%) | NS (0.1) | 1/33 (3%) |
−22q | 0/18 (0%) | NS (0.4) | 1/28 (4%) | NS (0.07) | 6/33 (18%) |
Mean number of CGH alterations | 2.2 | 0.0001 | 5.4 | NS (0.6) | 5.1 |
